Dipyridamole-associated headache in stroke patients--interindividual differences?

Area of Science:

• Neurology
• Pharmacology
• Cardiovascular Medicine

Background:

• Secondary prevention of ischemic stroke and TIA often uses acetylsalicylic acid (ASA), dipyridamole (DP), or both.
• Headache is a common side effect of DP, sometimes leading to treatment discontinuation.
• Titration regimens for DP can lower headache incidence, but interindividual differences are not well-studied.

Purpose of the Study:

• To investigate interindividual differences in headache incidence with a DP titration regimen.
• To explore the impact of age, gender, stroke localization, and time since onset on headache occurrence.

Main Methods:

• 174 ischemic stroke patients received a titration regimen of ASA 25 mg + DP 200 mg.
• Headache symptoms were self-reported daily for 10 days using a diary.
• Baseline characteristics and demographic data were recorded.

Main Results:

• 40.2% of patients reported headache, with 21.3% experiencing moderate/severe headache.
• Headache typically subsided within 3.1 days.
• Transient Ischemic Attack (TIA) patients had a higher headache risk; younger age and female gender showed a trend towards increased risk.

Conclusions:

• DP titration is associated with subsiding headaches, with few patients discontinuing medication.
• Younger females with TIA are at higher risk for DP-induced headaches.
• Adequate patient information on potential headaches is crucial for compliance and optimizing secondary stroke prevention.